🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

23 recruiting trials

for Locally Advanced Rectal Cancer (LARC)

Short-course Radiotherapy in TNT Combined With Enlonstobart for pMMR LARC NCT07448077Phase 21 site📍 Shijiazhuang Hebei Medical University Fourth Hospital · Tests: Experimental: short-course radiotherapy and immunotherapy, Chemoradiotherapy Total Neoadjuvant Treatment With or Without Tislelizumab for Locally Advanced Rectal Cancer. NCT06940388Phase 22 sites📍 Mainz📍 Petah Tikva brenner baruch · Tests: Tislelizumab, Total neoadjuvant therapy (TNT) Different-Dose SCRT Plus CAPOX, PD-1 Blockade and IL-2 in LARC NCT07646639Phase 21 site📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: Sintilimab + IL-2 Combined with CAPOX, Short-course low-dose radiotherapy, Short-course standard-dose radiotherapy SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC NCT07198165Phase 21 site📍 Shanghai Ruijin Hospital · Tests: PD-1 inhibitor based immunotherapy Short-course Radiotherapy Followed by AK112 and CAPOX as Neoadjuvant Therapy for Locally Advanced Rectal Cancer NCT06802666Phase 21 site📍 Hubei Union Hospital, Tongji Medical College, Huazhong University… · Tests: short-course radiotherapy, Ivonescimab, capecitabine, oxaliplatin, TME surgery Application of PET/MRI in the Evaluation of the Efficacy of Neoadjuvant Therapy for Locally Advanced Rectal Cancer NCT06653452NA1 site📍 Beijing Peking Union Medical College Hospital · Tests: 18F-FDG PET/CT and PET/MR scan, 68Ga-FAPI-04 PET/CT and PET/MR scan Neoadjuvant Long-course Chemoradiation Plus PD-1 Blockade for Mid-low Locally Advanced Rectal Cancer NCT05245474Phase 28 sites📍 Beijing📍 Beijing📍 Beijing Beijing Friendship Hospital · Tests: Long-course chemoradiation, with or without Tislelizumab (PD-1 inhibitor) Optimizing Immunotherapy Combined With Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer NCT07040098Phase 22 sites📍 Beijing📍 Shenzhen Cancer Institute and Hospital, Chinese Academy of Medical S… · Tests: Sintilimab, Short-course radiotherapy, Long-course concurrent chemoradiotherapy, CAPOX Clinical Trial of Neoadjuvant mFOLFOX Plus Alvenor for LARC Patients With High YWHAB Expression NCT07176182Phase 21 site📍 Guangzhou Sixth Affiliated Hospital, Sun Yat-sen University · Tests: mFOLFOX regimen combined with Citrus Flavone Tablets (Alvenor) neoadjuvant treatment group, mFOLFOX regimen neoadjuvant… SCRT Combined With Chemotherapy and Iparomlimab and Tuvonralimab in MSS or pMMR Patients With Locally Advanced Rectal Cancer NCT06864013Phase 21 site📍 Hangzhou First Affiliated Hospital of Zhejiang University · Tests: Experimental, Control SCRT VS LCRT Followed by PD-L1 Inhibitor Plus CAPEOX as TNT in Patients With LARC NCT07284992Phase 21 site📍 Jinan Shandong Provincial Hospital · Tests: short-term radiotherapy combined with Adebrelimab and capox, long-term radiotherapy combined with Adebrelimab and capox Personalized Long-course Radiotherapy Plus Chemotherapy With or Without Immunotherapy for LARC: PALACE Study NCT07020247Phase 31 site📍 Chengdu West China Hospital · Tests: Anti-PD-1 antibody drug named Serplulimab, Radiotherapy, Chemotherapy Application and Exploration of Personalized ctDNA-MRD Detection Technology in Predicting the Efficacy of Neoadjuvant Therapy for Rectal Cancer NCT07393048n/a1 site📍 Beijing Beijing Friendship Hospital · Tests: Personalized ctDNA-MRD Detection Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy, HLX07and Serplulimab in LARC NCT06542588Phase 23 sites📍 Wuhan📍 Wuhan📍 Hubei Union Hospital, Tongji Medical College, Huazhong University… · Tests: HLX07(anti EGFR antibody) and Serplulimab(anti PD-1 antibody) Radiotherapy Plus CAPOX, and Iparomlimab and Tuvonralimab (QL1706) as Neoadjuvant Therapy for LARC NCT07291401Phase 21 site📍 Wuhan Zhongnan Hospital · Tests: lparomlimab and Tuvonralimab Injection and CPAOX and radiotherapy SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC NCT07474103NA1 site📍 Wuhan Union Hospital, Tongji Medical College, Huazhong University… · Tests: SCRT, Liposomal Irinotecan, Oxaliplatin, Capecitabine, Sintilimab The Efficacy of Primary Total Mesorectal Excision (TME) Surgery Versus Neoadjuvant Chemotherapy Combined With TME Surgery in Low-risk Locally Advanced Rectal Cancer NCT05984485Phase 36 sites📍 Chongqing📍 Guangzhou📍 Hengyang Sun Yat-sen University · Tests: neoadjuvant chemotherapy plus total mesorectal excision, total mesorectal excision A Single-center, Phase II Study on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal Cancer NCT07347951Phase 21 site📍 Wenzhou First Affiliated Hospital of Wenzhou Medical University · Tests: Short-course radiotherapy, CAPOX chemotherapy, Targeted therapy with bevacizumab, Serplulimab immunotherapy Optimizing Patient Selection for Surgery Using Pathologic Analysis Following Neoadjuvant Therapy in Locally Advanced Rectal Cancer NCT06761287NA1 site📍 Brussels Centre Hospitalier Universitaire Saint Pierre · Tests: Endoscopic resection, Short interval restaging, Total mesorectal excision Real-world Efficacy and Safety of Neoadjuvant Dostarlimab in Patients With dMMR/MSI-H Locally Advanced Rectal Cancer NCT07269249n/a2 sites📍 Naples📍 Naples National Cancer Institute, Naples · Tests: Dostarlimab Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC. NCT06911684Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: lparomlimab and Tuvonralimab Injection and regorafenib and CPAOX and short-course radiotherapy, lparomlimab and Tuvonra… Evaluating a Nonessential Amino Acid Restriction (NEAAR) Medical Food With Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (LARC) NCT06380101NA1 site📍 Tampa University of South Florida · Tests: NEAAR Medical Food Modified Long-Course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for MSS/pMMR High-risk Mid/Low LARC (MODIFI-RC-I) NCT06923345Phase 21 site📍 Guangzhou Sixth Affiliated Hospital, Sun Yat-sen University · Tests: Reduced CTV, Conventional CTV
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy